Briefing
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
In the IMvigor010 correlative analysis, 214 of 581 evaluable people were ctDNA-positive and had a poor prognosis; atezolizumab improved disease-free and overall survival in that group and not in the ctDNA-negative group.
- Design: Evidence level 2
- Assay: Not named in the abstract